Company intelligence / Profile preview

Apimeds Pharmaceuticals US, Inc.

Matawan, New Jersey, United Statesapimeds.co.kr ↗

Ownership: Public · APUS
Employees: ~2
Development stage: Phase 3

Overview

Apimeds previously conducted a Phase 3 trial for knee osteoarthritis with approximately 330 patients, which demonstrated clinical efficacy and safety in a US population. However, the FDA determined in 2018 that a second confirmatory Phase 3 trial was needed because the study population was too small and the methods for handling missing data were inadequate.

Therapeutic areas: Rheumatology
Modalities: ToxinBee venom-based toxin
Industry: Biotech

Drug pipeline

2 assets

essential bee venom

1 more asset in the full pipeline.

Request access →

Financials

Market cap: $3.3M
Total revenue: $0
Enterprise value: $17.6M

Beyond the preview

Go deeper on Apimeds Pharmaceuticals US, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Apimeds Pharmaceuticals US, Inc..

Explore the full profile